alendronate and medroxyprogesterone acetate

alendronate has been researched along with medroxyprogesterone acetate in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (85.71)	29.6817
2010's	1 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Kokawa, Y; Naito, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G	1
Al, A; Bukulmez, O; Gurdal, H; Gurgan, T; Ulug, B; Yarali, H	1
Greenspan, SL; Parker, RA; Resnick, NM	1
Altintas, A; Baksu, B; Davas, I; Varolan, A; Yazgan, A; Yoldemir, T	1
Falbo, A; Lombardi, G; Manguso, F; Mastrantonio, P; Nunziata, V; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F	1
Cho, SH; Choi, YM; Lee, DY; Park, HM; Park, MC; Yoon, BK	1

Trials

5 trial(s) available for alendronate and medroxyprogesterone acetate

Article	Year
Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: a prospective randomized trial. Fertility and sterility, 2001, Volume: 75, Issue:4 Topics: Affect; Alendronate; Anxiety; Blood Platelets; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Imipramine; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Postmenopause; Prospective Studies; Tritium	2001
Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA, 2003, May-21, Volume: 289, Issue:19 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Osteoporosis, Postmenopausal; Progesterone Congeners	2003
Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. Fertility and sterility, 2003, Volume: 80, Issue:3 Topics: Absorptiometry, Photon; Administration, Cutaneous; Administration, Oral; Alendronate; Bone Density; Calcium; Drug Administration Schedule; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Progesterone Congeners	2003
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:8 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Combinations; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Genotype; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Receptors, Calcitriol; Selective Estrogen Receptor Modulators; Treatment Outcome	2005
Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial. Journal of Korean medical science, 2017, Volume: 32, Issue:6 Topics: Aged; Alendronate; Amino Acids; Asian People; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Lumbar Vertebrae; Mastodynia; Medroxyprogesterone Acetate; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Republic of Korea	2017

Other Studies

2 other study(ies) available for alendronate and medroxyprogesterone acetate

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
[Pain relief with alendronate therapy in a breast cancer patient with bone metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4 Topics: Aged; Alendronate; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Female; Floxuridine; Humans; Medroxyprogesterone Acetate; Pain; Sternum	2000

Article

Year

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Current drug discovery technologies, 2004, Volume: 1, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004

[Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].

Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4

Topics: Aged; Alendronate; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Female; Floxuridine; Humans; Medroxyprogesterone Acetate; Pain; Sternum

2000